MarketMoodz
NVO — Novo Nordisk A/S
Is NVO overbought or oversold? Here is the current MarketMoodz read.
Novo Nordisk A/S (NVO) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $50.43. The rating moved from Neutral to Overbought on June 27, 2026 and has changed 40 times in the last 90 days.
- Public ratingOverbought (as of July 5, 2026)
- Last close$50.43
- Rating changesRating changed 40 times in the last 90 days
- Last changeMoved from Neutral to Overbought on June 27, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - General
Latest MarketMoodz coverage
- Medicare to Temporarily Cover GLP‑1 Obesity Drugs Starting July 1, 20262026-06-30
- Medicare's Bridge to Cover GLP‑1 Obesity Drugs — Copay $50, Starts July 12026-06-28
- Zealand's Survodutide Readout Spurs Volatile Stock Reaction2026-06-19
- Zealand pivots to amylin as survodutide data sends stock tumbling2026-06-19
- Novo Nordisk Hackers Claim Theft of Drug Research, AI Models2026-06-17
See today's live rating, score and targets
Members see the live hourly rating for NVO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.